KEYTRUDA QLEX
offering product urn:matchory:offering:01m772jz8zeya84d0ezehf96qf
Offered by Merck & Co., Inc. urn:matchory:entity:01m772jvs7erfr0e1r838h4117 (entity). Relation: makes. Commodity: none confirmed.
An offering's identity is its owner, its commodity and its normalised name; it is never merged with another supplier's.
Facts
| Attribute | Value as written | Producer | Evidence | Observed | Status |
|---|---|---|---|---|---|
| Relation of the owner to it relation | makes | extraction extract 3 | we launched KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.https://www.merck.com/wp-content/uploads/sites/124/2026/08/PurposeforProgressMerckImpactReport2025-2026.pdf |
2026-11-12 | current |
| Name as stated name | KEYTRUDA QLEX | products products 2 | KEYTRUDA QLEXhttps://www.merck.com/wp-content/uploads/sites/124/2026/11/Public-Pipeline-4Q2026-Merck.pdf |
2026-11-12 | current |
| Name as stated name | KEYTRUDA QLEX | extraction extract 3 | we launched KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.https://www.merck.com/wp-content/uploads/sites/124/2026/08/PurposeforProgressMerckImpactReport2025-2026.pdf |
2026-11-12 | current |
| UNSPSC classification unspsc | no code (16 candidates considered) | classification unspsc 3 | 2026-11-12 | current |